Navigation Links
InNexus Biotechnology Receives Patent Grants in Europe
Date:10/30/2008

- CEO Morhet to Discuss Continued Expansion of DXL(TM) Patent Protection at

7th Annual BIO Investor Forum -

BRITISH COLUMBIA, Canada, Oct. 30 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced today that it has received patent grants in Germany, Spain, France, Great Britain and Italy further expanding patent protection of its DXL(TM) technology in Europe. The patents, titled "METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES," relate to the Company's ability to create, develop and manufacture antibodies based on its DXL(TM) technology platform. The new patents name InNexus scientists as inventors and are solely owned by InNexus.

"These patent grants demonstrate our commitment to providing real value to our shareholders by protecting and ensuring exclusivity of our DXL(TM) technology. Our patent portfolio provides potential for future royalty and licensing deals or outright sales of our expanding and maturing family of DXL(TM) preclinical candidates," said Jeff Morhet, Chairman and CEO of InNexus. "Patents are the currency of our industry and these patent grants also provide InNexus with additional tools to prevent others from making, using and selling DXL(TM) antibodies."

CEO Morhet will present at the 7th Annual BIO Investor Forum on October 30, 2008 and his thirty-minute presentation to potential investors and industry partners will begin at 3:15PM within the Twin Peaks South Room of the Palace Hotel in San Francisco, California. He will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform, partnerships, company milestones and the recent
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
2. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
3. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
4. InNexus Biotechnology Strengthens Patent Team With New Leadership
5. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
8. TechConnect World 2009 Matches Tomorrows Technology Solutions with Todays Business Needs for Clean-Technology, Biotechnology and Nanotechnology
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
11. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Iowa (PRWEB) September 02, 2014 Press ... of ways to take advantage of the people and ... the schedule below are available throughout the day. Additionally, ... requests with POET and DSM representatives as well as ... interview requests is appreciated. , Please remember to ...
(Date:9/2/2014)...  TransCelerate BioPharma Inc. ("TransCelerate") today announced that ... personal data in Clinical Study Reports (CSRs) that ... document describes an approach to apply when redacting ... related clinical trial documents, and is available ... TransCelerate CSR Redaction approach is to provide organizations ...
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... today announced positive results from its Phase IIa ... severely injured trauma patients with hemorrhagic shock causing ... given in addition to standard of care, was ... During hemorrhagic shock, inadequate perfusion of critical organs ...
... 31 Naurex Inc., a clinical stage company developing ... reported that its clinical stage candidate for the treatment ... been selected for inclusion on Windhover,s list of the ... were chosen by a committee that included Windhover Information, ...
... SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... of Julie M. Eastland as Chief Financial Officer ... 2010. Ms. Eastland,s responsibilities will include financial management, ... Eastland brings more than 25 years of financial ...
Cached Biology Technology:Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 2Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 3Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 2Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 3Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 4Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 5ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... EDT) It may be possible to train the ... foods, according to new research by scientists at the ... (USDA HNRCA) at Tufts University and at Massachusetts General ... & Diabetes , a brain scan study in adult ... reverse the addictive power of unhealthy food while also ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2
... inbreeding is a threat against the viabi lity of ... in the new journal PLoS ONE now demonstrates that ... expected. The results show that it is the most ... breeding population. An important consequence of this action of ...
... has discovered that some stealthy mammals have been doing something ... water. , The results of the research by Vanderbilt's Kenneth ... the science journal Nature. He became curious when he observed ... bubbles while swimming. , "This came as a ...
... which can become less effective over time, might retain ... second drug, according to new research in mice conducted ... of the National Institutes of Health, and their partners. ... of Cancer Cell*. , Tamoxifen has been used successfully ...
Cached Biology News:Wolves are suffering less from inbreeding than expected 2Contrary to common wisdom, scientist discovers some mammals can smell objects under water 2Contrary to common wisdom, scientist discovers some mammals can smell objects under water 3Restoring tamoxifen sensitivity in resistant breast cancer cells 2
Taq DNA polymerase, 10,000U...
... AmpliTaq DNA Polymerase is the ... PCR process, a testimony to its overall ... profile makes it ideal for PCR applications. ... guarantee reproducible results. ,, AmpliTaq DNA ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Biology Products: